<DOC>
	<DOCNO>NCT01355614</DOCNO>
	<brief_summary>This study ass safety efficacy QAX576 patient fistulizing Crohn 's disease .</brief_summary>
	<brief_title>A Phase II Efficacy Study Fistulizing Crohn 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>At least one drain enterocutaneous perianal fistula Diagnosis Crohn 's disease ( CD ) must establish least 6 month At least one ineffective fistula treatment ( previously fail antiTNFα ( tumour necrosis factor ) antibody treatment ) Patients suffer health problem may jeopardize participation study . Current recent ( within 30 day enrollment , 5 halflives compound , whichever long ) use antiTNFα antibody treatment Active Crohn 's disease Recent pending abdominal anorectal surgery , particularly presence stricture , abscess , retention surgery might indicate Previously fail antiTNFα antibody treatment Intercurrent bacterial viral ( intestinal ) infection ( serologically microbiologically confirm ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Fistula</keyword>
</DOC>